IP Library › Granted Patent US 12,442,021
Granted Patent B2
US 12,442,021 · App. 18/063,511 · Granted Oct 14, 2025

Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies

Inventors: Jennifer E. Adair (Seattle, WA); Reza Shahbazi (Seattle, WA)
Assignee: Fred Hutchinson Cancer Center
C12N15/907A61K40/10A61K40/40A61K47/6929C12N5/0634C12N9/22C12N15/113A61K2239/31A61K2239/38C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,442,021
App. No.
18/063,511
Granted
Oct 14, 2025
Kind
B2
Abstract

Genomic safe harbors (GSH) for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies are described. The GSH and/or associated nanoparticles can be used to safely and efficiently treat a variety of genetic, infectious, and malignant diseases.

Claims (34)

1. A therapeutic formulation comprising a nanoparticle (NP) and a pharmaceutically acceptable carrier, the NP comprising:

a metallic core associated with a first NP layer and a second NP layer, wherein the first NP layer comprises:

a crRNA with a 3′ end and a 5′ end,

wherein the 3′ end is conjugated to a spacer with a thiol modification, and the 5′ end is conjugated to a nuclease to form a crRNA-nuclease ribonucleoprotein (RNP) complex,

wherein the thiol modification is covalently linked to the surface of the metallic NP core and

wherein the crRNA-nuclease RNP complex binds a target PAM-site within human (h) chromosome (chr) 11 at positions 67681215-67741765; 67691162-67691186; 67723825-67723849; 67805337-67845629; 67812349-67812375; 67812443-67812469; 67839126-67839150; or 67895738-67941098 or hchr3 at positions 46373915-46373939,

and wherein the second NP layer comprises a donor template comprising a therapeutic gene and homology-directed repair templates, and wherein the second NP layer is farther from the surface of the metallic core than the first NP layer.

2. The therapeutic formulation of claim 1 , wherein the metallic core is gold.

3. The therapeutic formulation of claim 1 , where the nanoparticle further comprises a polymer coating.

4. The therapeutic formulation of claim 1 , wherein the crRNA-nuclease RNP complex binds to one of SEQ ID Nos: 1-194, 197-208, 213, 242, 245, 251, 254, 258, or 263.

5. The therapeutic formulation of claim 1 , wherein the nuclease is Cpf1 or Cas 9.

6. The therapeutic formulation of claim 1 , wherein the crRNA comprises SEQ ID NO:

195, 196, 209, 211, 244, 253, 260, or 264.

7. The therapeutic formulation of claim 1 , wherein the nuclease comprises a sequence selected from SEQ ID NOs: 215-241 or a variant of a Cpf1 selected from SEQ ID NOs: 216-227, or 229-241.

8. The therapeutic formulation of claim 1 , wherein the nanoparticle is coupled to a targeting molecule.

9. The therapeutic formulation of claim 8 , wherein the targeting molecule comprises a CD34 binding domain or a CD90 binding domain.

10. The therapeutic formulation of claim 1 , wherein the nanoparticles have an average diameter of 25-30 nm.

11. The therapeutic formulation of claim 1 , wherein the nanoparticles have a hydrodynamic size of 150-190 nm, 160-185 nm, 170-180 nm, or 176 nm.

12. A method of providing a therapeutic gene to a patient in need thereof comprising administering the therapeutic formulation of claim 1 to the patient thereby providing the therapeutic gene to the patient.

13. The method of claim 12 , wherein the therapeutic formulation is administered by injection, infusion, perfusion, or lavage.

14. A method of providing a therapeutic gene to a patient in need thereof comprising administering a therapeutic formulation to the patient,

wherein the therapeutic formulation comprises a cell genetically modified by a nanoparticle (NP) comprising a metallic NP core associated with a first NP layer and a second NP layer, wherein the first NP layer comprises

a crRNA with a 3′ end and a 5′ end,

wherein the 3′ end is conjugated to a spacer with a thiol modification, and the 5′ end is conjugated to a nuclease to form a crRNA-nuclease ribonucleoprotein (RNP) complex,

wherein the thiol modification is covalently linked to a surface of the metallic NP core and

wherein the crRNA-nuclease RNP complex binds a target PAM-site within human (h) chromosome (chr) 11 at positions 67681215-67741765; 67691162-67691186; 67723825-67723849; 67805337-67845629; 67812349-67812375; 67812443-67812469; 67839126-67839150; or 67895738-67941098 or hchr3 at positions 46373915-46373939;

and wherein the second NP layer comprises a donor template comprising a therapeutic gene and homology-directed repair templates; and wherein the second NP layer is farther from the surface of the metallic NP core than the first NP layer,

thereby providing the therapeutic gene to the patient.

15. The method of claim 14 , wherein the therapeutic formulation further comprises serum components.

16. The method of claim 14 , wherein the patient in need thereof has been diagnosed with a monogenetic blood disorder, hemophilia, Grave's Disease, rheumatoid arthritis, pernicious anemia, Multiple Sclerosis (MS), inflammatory bowel disease, systemic lupus erythematosus (SLE), Wiskott-Aldrich syndrome (WAS), chronic granulomatous disease (CGD), Battens disease, adrenoleukodystrophy (ALD) or metachromatic leukodystrophy (MLD), muscular dystrophy, pulmonary aveolar proteinosis (PAP), pyruvate kinase deficiency, Shwachmann-Diamond-Blackfan anemia, dyskeratosis congenita, cystic fibrosis, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (Lou Gehrig's disease), acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), agnogenic myeloid metaplasia, amegakaryocytosis/congenital thrombocytopenia, ataxia telangiectasia, β-thalassemia major, CLL, chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia, common variable immune deficiency (CVID), complement disorders, congenital (Xlinked) agammaglobulinemia, familial erythrophagocytic lymphohistiocytosis, Hodgkin's lymphoma, Hurler's syndrome, hyper IgM, IgG subclass deficiency, juvenile myelomonocytic leukemia, mucopolysaccharidoses, multiple myeloma, myelodysplasia, non-Hodgkin's lymphoma, paroxysmal nocturnal hemoglobinuria (PNH), primary immunodeficiency diseases with antibody deficiency, pure red cell aplasia, refractory anemia, selective IgA deficiency, severe aplastic anemia, SCD, specific antibody deficiency, a bacterial infection, or a parasitic infection.

17. The method of claim 14 , wherein the therapeutic formulation is administered by injection, infusion, perfusion, or lavage.

18. The method of claim 14 , wherein the cell is a hematopoietic stem cell (HSC), a hematopoietic progenitor cell (HPC), a hematopoietic stem and progenitor cell (HSPC), a T cell, a natural killer (NK) cell, a B cell, a macrophage, a monocyte, a mesenchymal stem cell (MSC), a white blood cell (WBC), a mononuclear cell (MNC), an endothelial cell (EC), a stromal cell, and/or a bone marrow fibroblast.

19. The method of claim 14 , wherein the cell is a CD 34 +CD45RA-CD90 + HSC.

20. The method of claim 14 , wherein the cell is a human blood cell.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2022
From: ADAIR, JENNIFER E.
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 062129/0804 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2022
From: ADAIR, JENNIFER E.; SHAHBAZI, REZA
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 062130/0089 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2022
From: ADAIR, JENNIFER E.; SHAHBAZI, REZA
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 062130/0321 →
MERGER AND CHANGE OF NAME Recorded Dec 16, 2022
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 062130/0481 →
Continuity (5)
Continuation 16619211
Provisional Application 62664045 · Apr 27, 2018
Provisional Application 62564129 · Sep 27, 2017
Provisional Application 62515474 · Jun 5, 2017
Related Publication 20230279441A1 · Sep 7, 2023
References Cited (129)
US 8697359B1 · Zhang · 2014 [cited by applicant]
US 8771945B1 · Zhang · 2014 [cited by applicant]
US 8795965B2 · Zhang · 2014 [cited by applicant]
US 8865406B2 · Zhang et al. · 2014 [cited by applicant]
US 8871445B2 · Cong et al. · 2014 [cited by applicant]
US 8889356B2 · Zhang · 2014 [cited by applicant]
US 8889418B2 · Zhang et al. · 2014 [cited by applicant]
US 8895308B1 · Zhang et al. · 2014 [cited by applicant]
US 8906616B2 · Zhang et al. · 2014 [cited by applicant]
US 8932814B2 · Cong et al. · 2015 [cited by applicant]
US 8945839B2 · Zhang · 2015 [cited by applicant]
US 8993233B2 · Zhang et al. · 2015 [cited by applicant]
US 8999641B2 · Zhang et al. · 2015 [cited by applicant]
US 9580701B2 · May et al. · 2017 [cited by applicant]
US 20010005581A1 · Grant et al. · 2001 [cited by applicant]
US 20030053983A1 · Tamarkin et al. · 2003 [cited by applicant]
US 20030118657A1 · West et al. · 2003 [cited by applicant]
US 20080050774A1 · Berka et al. · 2008 [cited by applicant]
US 20160208243A1 · Zhang et al. · 2016 [cited by applicant]
US 20170058272A1 · Carter et al. · 2017 [cited by applicant]
US 20170106025A1 · Kovarik · 2017 [cited by applicant]
US 20180030425A1 · Joung et al. · 2018 [cited by applicant]
US 20190345450A1 · Radtke et al. · 2019 [cited by applicant]
US 20210171983A1 · Adair et al. · 2021 [cited by applicant]
WO WO2014018423 · 2014 [cited by applicant]
WO WO2014093595A1 · 2014 [cited by applicant]
WO WO2014093622A2 · 2014 [cited by applicant]
WO WO2014093635A1 · 2014 [cited by applicant]
WO WO2014093655A2 · 2014 [cited by applicant]
WO WO2014093661A2 · 2014 [cited by applicant]
WO WO2014093694A1 · 2014 [cited by applicant]
WO WO2014093701A1 · 2014 [cited by applicant]
WO WO2014093709A1 · 2014 [cited by applicant]
WO WO2014093712A1 · 2014 [cited by applicant]
WO WO2014093718A1 · 2014 [cited by applicant]
WO WO2014145599A2 · 2014 [cited by applicant]
WO WO2014204723A1 · 2014 [cited by applicant]
WO WO2014204724A1 · 2014 [cited by applicant]
WO WO2014204725A1 · 2014 [cited by applicant]
WO WO2014204726A1 · 2014 [cited by applicant]
WO WO2014204727A1 · 2014 [cited by applicant]
WO WO2014204728A1 · 2014 [cited by applicant]
WO WO2014204729A1 · 2014 [cited by applicant]
WO WO2015048577A2 · 2015 [cited by applicant]
WO WO2015065964A1 · 2015 [cited by applicant]
WO WO2015089351A1 · 2015 [cited by applicant]
WO WO2015089354A1 · 2015 [cited by applicant]
WO WO2015089364A1 · 2015 [cited by applicant]
WO WO2015089419A2 · 2015 [cited by applicant]
WO WO2015089427A1 · 2015 [cited by applicant]
WO WO2015089462A1 · 2015 [cited by applicant]
WO WO2015089465A1 · 2015 [cited by applicant]
WO WO2015089473A1 · 2015 [cited by applicant]
WO WO2015089486A2 · 2015 [cited by applicant]
WO WO2016094874A1 · 2016 [cited by applicant]
WO WO2016118780A1 · 2016 [cited by applicant]
WO WO2016205711A1 · 2016 [cited by applicant]
WO WO2017004261A1 · 2017 [cited by applicant]
WO WO2017015015A1 · 2017 [cited by applicant]
WO 2017053312A1 · 2017 [cited by applicant]
WO WO2017053713A1 · 2017 [cited by applicant]
WO WO2016115179A1 · 2017 [cited by applicant]
WO WO2017062983A1 · 2017 [cited by applicant]
WO WO2017066588A2 · 2017 [cited by applicant]
WO WO2017106657A1 · 2017 [cited by applicant]
WO WO2017127807A1 · 2017 [cited by applicant]
WO WO2017184768A1 · 2017 [cited by applicant]
WO WO2017218948A2 · 2017 [cited by applicant]
Yan, et al., “BLISS is a versatile and quantitative method for genome-wide profiling of DNA double-strand breaks.” Nat. Commun., vol. 8, 2017, 9 pages. [cited by applicant]
Yin, et al., “CRISPR-Cas9 and CRISPR-Cpf1 mediated targeting of a stomatal developmental gene EPFL9 in rice,” Plant Cell Rep., vol. 36, No. 5, 2017, pp. 745-757. [cited by applicant]
Yin, et al., “Delivery technologies for genome editing,” Nat. Rev., vol. 16, 2017, pp. 387-399. [cited by applicant]
Zaidi, et al., “CRISPR-Cpf1: A New Tool for PLant Genome Editing,” Cell Press, vol. 22, No. 7, 2017, pp. 550-553. [cited by applicant]
Zetsche, et al., “Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System,” Cell, vol. 163, No. 3, 2015, pp. 795-771. [cited by applicant]
Zetsche, et al., “Multiplex gene editing by CRISPR-Cpf1 through autonomous processing of a single crRNA array,” Nat. Biotechnol., vol. 35, No. 1, 2017, pp. 31-34. [cited by applicant]
Zhang, et al., “CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomycocytes and mice,” Sci. Adv., vol. 3, No. 4, 2017, pp. 1-10. [cited by applicant]
Zhang, et al., “Instantaneous and Quantitative Functionalization of Gold Nanoparticles With Thiolated DNA Using a pH-assisted and Surfactant-Free Route,” J. Am. Chem. Soc., vol. 134. No. 17, 2012, pp. 7266-7269. [cited by applicant]
Zhang, et al., “Multiplex gene regulation by CRISPR-ddCpf1,” Cell Discovery, vol. 3, 2017, pp. 1-9. [cited by applicant]
Zhong, et al., “Cpf1 proteins excise CRISPR RNAs from mRNA transcripts in mammalian cells,” Nat. Chem. Biol., vol. 13, No. 8, 2017, pp. 834-841. [cited by applicant]
Office Action for Canadian Application No. 3,102,054, Dated Jul. 31, 2024, 6 pages. [cited by applicant]
Bedel, et al., “Metabolic Correction of Congenital Erythropoietic Porphyria with iPSCs Free of Reprogramming Factors”, The American Journal of Human Genetics, vol. 91, No. 1, May 31, 2012, pp. 109-121. [cited by applicant]
Bibikova, et al., “Enhancing Gene Targeting with Designed Zinc Finger Nucleases,” Science, vol. 300, 2003, 1 page. [cited by applicant]
Bibikova, et al., “Targeted Chromosomal Cleavage and Mutagenesis in Drosophila Using Zinc-Finger Nucleases,” Genetics, vol. 161, 2002, pp. 1169-1175. [cited by applicant]
Boch, et al., “Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors,” Science, vol. 326, 2009, pp. 1509-1512. [cited by applicant]
Bonifant, et al., “Toxicity and management in CAR T-cell therapy,” Mol. Ther. Oncolytics, vol. 3, 2016, 7 pages. [cited by applicant]
Chang & Wilson, “Modification of DNA ends can decrease end joining relative to homologous recombination in mammalian cells,” PNAS, vol. 84, No. 14, 1987, pp. 4959-4963. [cited by applicant]
Choudhary, et al., “Knockdown of HPRT for Selection of Genetically Modified Human Hematopoietic Progenitor Cells,” PLoS One, vol. 8, No. 3, 2013, 9 pages. [cited by applicant]
Christian, et al., “Targeting DNA Double-Strand Breaks with TAL Effector Nucleases,” Genetics, vol. 186, 2010, pp. 757-761. [cited by applicant]
Corrigan-Curay, et al., “Genome Editing Technologies: Defining a Path to Clinic”, Molecular Therapy, vol. 23, No. 5, May 1, 2015, pp. 796-806. [cited by applicant]
De Ravin et al., “CRISPR-Cas9 Gene Repair of Hematopoietic Stem Cells From Patients With X-linked Chronic Granulomatous Disease,” Sci. Transl. Med., vol. 9, No. 372, 2017, 10 pages. [cited by applicant]
Ding et al., “Gold Nanoparticles for Nucleic Acid Delivery,” Molecular Therapy, vol. 22, No. 6, 2014, pp. 1075-1083. [cited by applicant]
Dong, et al., “The Crystal Structure of Cpf1 in Complex With Crispr RNA,” Nature, vol. 532, No. 7600, 2016, pp. 522-526. [cited by applicant]
Extended European Search Report mailed Feb. 11, 2021 for European Patent Application No. 18812653.6, 9 pages. [cited by applicant]
Genbank, “ [cited by applicant]
Gori, et al., “In vivo Selection of Autologous MGMT Gene-Modified Cells Following Reduced Intensity Conditioning with BCNU and Temozolomide in the Dog Model,” Cancer Gene. Ther., vol. 19, No. 8, 2012, pp. 523-529. [cited by applicant]
Hakkinen, “The Gold-Sulfur Interface at the Nanoscale,” Nat. Chem., vol. 4, No. 6, 2012, pp. 443-455. [cited by applicant]
Huang, et al., “Cancer Cell Targeting Using Multiple Aptamers Conjugated on Nanorods,” Anal. Chem., vol. 80, No. 3, 2008, pp. 567-572. [cited by applicant]
Jiang, et al., “CRISPR-Cpf1 assisted genome editing of Corynebacterium glutamicum,” Nat. Commun., vol. 8, No. 15179, 2017, pp. 1-11. [cited by applicant]
Kennedy, et al., “Ex Vivo y-Retroviral Gene Therapy of Dogs with X-linked Severe Combined Immunodeficiency and the Development of a Thymic T Cell Lymphoma,” Vet. Immunol. Immunopathol., vol. 142, No. 1-2, 2011, pp. 36-4… [cited by applicant]
Kim, et al., “CRISPR/Cpf1-mediated DNA-free plant genome editing,” Nat. Comm., vol. 8, No. 14406, 2017, pp. 1-7. [cited by applicant]
Kim, et al., “Efficient Transcriptional Gene Repression by Type V-A CRISPR-Cpf1 from Eubacterium eligens,” ACS. Synth. Biol., vol. 6, No. 7, 2017, pp. 1273-1282. [cited by applicant]
Kim, et al., “Genome-wide Analysis Reveals Specificities of Cpf1 Endonucleases in Human Cells,” Nat. Biotechnol., vol. 34, No. 8, 2016, pp. 863-868. [cited by applicant]
Kim, et al., “Hybrid restriction enzymes Zinc finger fusion to Fok I cleavage domain,” PNAS, vol. 93, 1996, pp. 1156-1160. [cited by applicant]
Lee, et al., “Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair,” Nat. Biomed. Eng., vol. 1, 2017, pp. 889-901. [cited by applicant]
Li, et al., “Engineering CRISPR-Cpf1 crRNAs and mRNAs to maximize genome editing efficiency,” Nat. Biomed. Eng., vol. 1, No. 5, 2017, 21 pages. [cited by applicant]
Miller, et al., “A TALE nuclease architecture for efficient genome editing,” Nat. Biotechl., vol. 29, No. 2, 2011, pp. 143-150. [cited by applicant]
Miller, et al., “An improved zinc-finger nuclease architecture for highly specific genome editing,” Nat. Biotechnol., vol. 25, No. 7, 2007, pp. 778-785. [cited by applicant]
Miller, et al., “Repetitive Zinc-Binding Domains in the Protein Transcription Factor IIIA From Xenopus Oocytes,” EMBO J., vol. 4, No. 6, 1985, pp. 1609-1614. [cited by applicant]
Mirkin, et al., “A DNA-based Method for Rationally Assembling Nanoparticles Into Macroscopic Materials,” Nature, vol. 382, No. 6592, 1996, pp. 607-609. [cited by applicant]
Moscou & Bogdanove, “A Simple Cipher Governs DNA Recognition by TAL Effectors,” Science, vol. 326, 2009, pp. 1501. [cited by applicant]
Nehls, et al., “Two Genetically Separable Steps in the Differentiation of Thymic Epithelium,” Science, vol. 272, No. 5263, 1996, pp. 886-889. [cited by applicant]
Papapetrou & Schambach, “Gene Insertion Into Genomic Safe Harbors for Human Gene Therapy,” Mol. Ther., vol. 24, No. 4, 2016. pp. 678-684. [cited by applicant]
Papapetrou, et al., “Genomic safe harbors permit high beta-globin transgene expression in thalassemia induced pluripotent stem cells,” Nat. Biotechnol., vol. 29, No. 1, 2011, pp. 73-78. [cited by applicant]
Invitation to Pay Additional Fees Dated Aug. 14, 2018 in International Application No. PCT/US18/36154, 3 pages. [cited by applicant]
Search Report and Written Opinion Dated Oct. 26, 2018 for International Application No. PCT/US18/36154, 17 pages. [cited by applicant]
Pellenz, et al., “New Human Chromosomal Sites with Safe Harbor Potential for Targeted Transgene Insertion”, Human Gene Therapy, vol. 30, No. 7, 2019, 15 pages. [cited by applicant]
Perrault & Chan, “Synthesis and Surface Modification of Highly Monodispersed, Spherical Gold Nanoparticles of 50-200 Nm,” J. Am. Chem. Soc., vol. 131, No. 47, 2009, pp. 17042-17043. [cited by applicant]
Radtke, et al., “A distinct hematopoietic stem cell population for rapid multilineage engraftment in nonhuman primates,” Sci. Transl. Med., vol. 9, No. 414, 2017, 22 pages. [cited by applicant]
Ran, et al., “Double Nicking by RNA-guided CRISPR Cas9 for Enhanced Genome Editing Specificity,” Cell, vol. 154, No. 6, 2013, pp. 1380-1389. [cited by applicant]
Richardson, et al., “Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA,” Nat. Biotechnol., vol. 34, No. 3, 2016, pp. 339-344. [cited by applicant]
Sadelain, et al., “Safe Harbours for the Integration of New DNA in the Human Genome”, Nature Reviews Cancer, vol. 12, No. 1, Jan. 1, 2011, pp. 51-58. [cited by applicant]
Sayandip, et al., “Gene Therapy for PIDs: Progress, Pitfalls and Prospects”, Gene, vol. 525, No. 2, Apr. 6, 2013, pp. 174-181. [cited by applicant]
Shahbazi, et al., “Functionalized Gold Nanoparticles Manifested as Potent Carriers for Nucleolar Targeting,” Nanotechnology, vol. 28, No. 2, 2017, 12 pages. [cited by applicant]
Shahbazi, et al., “Modified Gold-Based siRNA Nanotherapeutics for Targeted Therapy of Triple-Negative Breast Cancer,” Nanomedicine, vol. 12, No. 16, 2017, pp. 1961-1973. [cited by applicant]
Supplementary Table XP55767862, “Nucleotide Sequence Variants in mCrel Genomic Target Sites, Together with Predicted Effect on mCrel Cleavage Sensitivity”, retrieved on Jan. 22, 2021 from https://www.ncbi.nlm.nih.gov/pm… [cited by applicant]
Tang, et al., “A CRISP-Cpf1 system for efficient genome editing and transcriptional repression in plants,” Nat. Plants., vol. 3, No. 17018, 2017, 21 pages. [cited by applicant]
Turkevich, et al., “A study of the nucleation and growth processes in the synthesis of colloidal gold,” Discussions of the Faraday Society, vol. 11, No. 0, 1951, pp. 55-75. [cited by applicant]
Wisniewski, et al., “Further phenotypic characterization of the primitive lineage—CD34+CD38-CD90+CD45RA-hematopoietic stem cell/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and pat… [cited by applicant]
Wolfe, et al., “DNA Recognition by Cys2His2 Zinc Finger Proteins,” Ann. Rev. Biophy. Biomol., vol. 29, 2000, pp. 183-212. [cited by applicant]
Xu, et al., “Generation of targeted mutant rice using a CRISPR-Cpf1 system,” Plant Biotechnol. J., vol. 15, No. 6, 2017, pp. 713-717. [cited by applicant]